Teresa McIlvoy, APRN
Psychiatric/Mental Health · Danville, KYNPI 1235580754
Payments from drug & device makers
Across 302 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$813
- AbbVie$738
- Axsome Therapeutics, Inc.$431
- Otsuka America Pharmaceutical, Inc.$418
- Alkermes, Inc.$413
- Corium, LLC$389
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $813 |
| AbbVie | 43 | $738 |
| Axsome Therapeutics, Inc. | 19 | $431 |
| Otsuka America Pharmaceutical, Inc. | 25 | $418 |
| Alkermes, Inc. | 24 | $413 |
| Corium, LLC | 22 | $389 |
| Supernus Pharmaceuticals, Inc. | 14 | $387 |
| Vanda Pharmaceuticals Inc. | 26 | $368 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $256 |
| E.r. Squibb & Sons, L.L.C. | 10 | $212 |
| Almatica Pharma LLC | 8 | $196 |
| Lundbeck LLC | 7 | $152 |
| Teva Pharmaceuticals USA, Inc. | 7 | $140 |
| Neurocrine Biosciences, Inc. | 8 | $135 |
| Johnson & Johnson | 4 | $119 |
| Biogen | 5 | $85 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Merck | 1 | $23 |
| Amgen | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,458 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $137,310 |
| RexultiBrexpiprazole | 55 | $97,275 |
| Invega SustennaPaliperidone Palmitate | 11 | $33,727 |
| TrintellixVortioxetine Hydrobromide | 32 | $17,053 |
| Aripiprazole | 52 | $11,449 |
| Lurasidone Hcl | 41 | $5,191 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 84 | $2,716 |
| Olanzapine | 26 | $1,396 |
| Trazodone Hcl | 103 | $1,267 |
| Clonazepam | 169 | $1,210 |
| Quetiapine Fumarate | 52 | $1,020 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $776 |
| Duloxetine Hcl | 27 | $654 |
| Hydroxyzine Pamoate | 41 | $473 |
| Bupropion XlBupropion Hcl | 51 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $135 | $137,31013 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $418 | $97,27555 claims |
| Johnson & JohnsonInvega Sustenna | $119 | $33,72711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $256 | $17,05332 claims |
| Lilly USA, LLCOlanzapine | $12 | $1,39626 claims |
| Almatica Pharma LLCSertraline Hcl | $196 | $37550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Danville
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.